Innate Pharma Sa SEC Filings

Innate Pharma S.A., a clinical-stage immuno-oncology company listed on Euronext Paris and Nasdaq, announced that Chief Operating Officer Yannis Morel will present at the AACR Oncology Industry Partnering Event in San Diego. The April 16, 2026 showcase session will allow Innate to highlight its oncology pipeline, including key assets such as IPH4502, a Nectin4 antibody-drug conjugate for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab, developed with AstraZeneca, for non-small cell lung cancer. The company views this invitation as recognition of its clinical pipeline and an opportunity to engage directly with investors and industry partners.

Innate Pharma S.A., a clinical-stage biotechnology company developing cancer immunotherapies, reported that its executive team will participate in one-on-one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15–16, 2026.

The company highlights its portfolio of antibody-based therapies, including IPH4502, lacutamab and monalizumab, and notes ongoing collaborations with major partners such as AstraZeneca and Sanofi. The notice also reiterates that investors should refer to its French Universal Registration Document and Form 20-F for detailed risk factors.

Innate Pharma S.A. has filed its 2025 Universal Registration Document with the French market authority AMF and its 2025 Form 20-F annual report with the U.S. SEC, both covering the year ended December 31, 2025. These filings include the annual financial report, management report, corporate governance report, and statutory auditors’ report.

Innate Pharma is a clinical-stage biotechnology company focused on cancer immunotherapies, developing next-generation antibody-based drugs such as IPH4502, lacutamab and monalizumab, in collaboration with partners including AstraZeneca and Sanofi.

Innate Pharma S.A. files its Form 20‑F annual report, describing a clinical‑stage, oncology‑focused biotech developing immuno‑oncology antibodies, including checkpoint inhibitors and its ANKET® multi‑specific platform. Financial statements are prepared under IFRS Accounting Standards and presented in euros.

The report emphasizes that most product candidates are in early clinical or preclinical stages, with high development uncertainty, reliance on partners AstraZeneca and Sanofi, and significant dependence on additional financing. It highlights extensive regulatory, clinical, competitive and reimbursement risks, and notes orphan drug, fast track, PRIME and Breakthrough Therapy designations for lacutamab as important but not guaranteed paths to faster approval. Ordinary shares outstanding were 93,719,323 as of December 31, 2025.

Innate Pharma S.A. reported a 2025 net loss of €49.2 million, broadly in line with 2024, as revenue and other income fell 55% to €9.0 million mainly due to lower collaboration and licensing revenue from AstraZeneca and Sanofi.

Cash, cash equivalents, short-term investments and financial assets totaled €44.8 million as of December 31, 2025, giving an estimated cash runway only until the end of Q3 2026. Shareholders’ equity turned negative at €(21.7) million, and the company states there is substantial doubt about its ability to continue as a going concern while it pursues non-dilutive financing options.

R&D expenses declined 16% to €43.6 million as the pipeline was strategically refocused, including discontinuation of IPH6501, while key programs such as lacutamab, IPH4502 and partnered assets with AstraZeneca and Sanofi continue to advance toward significant data and regulatory milestones in 2026.

Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.

Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.

Innate Pharma SA ownership update: Novo Nordisk A/S reports beneficial ownership of 7,333,778 ordinary shares, representing 7.82% of the class as of 12/31/2025. The filing shows sole voting and dispositive power over 7,333,778 shares.

The form is an amended Schedule 13G/A filed and signed on 03/04/2026 by Karsten Munk Knudsen, Chief Financial Officer.

Innate Pharma S.A. filed a report noting that its executive team will take part in the Leerink Partners Global Healthcare Conference 2026 in Miami from March 8–11. The company will host a fireside chat on March 9 at 3:40 PM ET, with a live webcast and replay available through the Investors section of its website.

The filing also highlights Innate Pharma’s focus on developing next-generation antibody-based immunotherapies for cancer, including IPH4502, lacutamab and monalizumab, and mentions ongoing collaborations with major partners such as AstraZeneca and Sanofi.

Innate Pharma SA filed an amended ownership report showing that AstraZeneca PLC and its wholly owned subsidiary MedImmune Limited together beneficially own 7,825,501 Ordinary Shares, including 1,565,001 shares represented by ADSs. This stake represents 8.3% of Innate Pharma’s Ordinary Shares, based on 93,719,323 shares outstanding as of December 31, 2025, as disclosed in a recent Form 6-K. AstraZeneca PLC and MedImmune Limited are each deemed to have sole voting and dispositive power over all shares held by MedImmune Limited, and neither the reporting entities nor their listed directors and officers have traded Innate Pharma shares in the past 60 days.